会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 36. 发明申请
    • METHODS FOR DIAGNOSING OR PROGNOSING PROSTATE CANCER
    • 诊断或预测前列腺癌的方法
    • WO2017102838A1
    • 2017-06-22
    • PCT/EP2016/080992
    • 2016-12-14
    • INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)UNIVERSITE NICE SOPHIA ANTIPOLIS
    • BENAHMED, Mohamed
    • C12Q1/68
    • C12Q1/6886C12Q2600/158C12Q2600/178
    • The present invention relates to methods and kits for diagnosing or prognosing prostate cancer. More particularly, the invention relates to an in vitro method for predicting or diagnosing a prostate cancer in a subject, said method comprising the following steps of: i) measuring the expression levels of miR-101 and miR-145 in a biological sample obtained from said subject; ii) comparing said expression levels of miR-101 and miR-145 with their respective predetermined reference values; and iii) determining whether the subject has or is at risk of having a prostate cancer, wherein an expression level of miR-101 lower than the predetermined reference value and an expression level of miR-145 higher than the predetermined reference value is indicative that the subject has, or is at risk of having a prostate cancer.
    • 本发明涉及诊断或预后前列腺癌的方法和试剂盒。 更特别地,本发明涉及用于预测或诊断受试者中的前列腺癌的体外方法,所述方法包括以下步骤:i)测量获自以下的生物样品中miR-101和miR-145的表达水平: 说的话题; ii)比较miR-101和miR-145的所述表达水平与它们各自的预定参考值; 和iii)确定受试者是否患有前列腺癌或处于患有前列腺癌的风险中,其中miR-101的表达水平低于预定参考值并且miR-145的表达水平高于预定参考值表示 受试者患有或有患前列腺癌的风险。
    • 39. 发明申请
    • PANICEIN COMPOUNDS, COMPOSITIONS AND USES THEREOF
    • 泛素化合物,组合物及其用途
    • WO2016066594A1
    • 2016-05-06
    • PCT/EP2015/074771
    • 2015-10-26
    • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEUNIVERSITE NICE SOPHIA ANTIPOLIS
    • MUS-VETEAU, IsabelleTHOMAS, OlivierTRIBALAT, Marie-Aude
    • A61K31/05A61K31/11A61K31/353A61P35/00
    • A61K31/05A61K31/11A61K31/353
    • The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
    • 本发明涉及药物和癌症治疗领域。 本发明更具体地涉及使用Panicein或其衍生物在体外或体外抑制Patched受体药物外排活性,特别是化疗药物外排活性和化疗耐药性的用途。 本公开还涉及这种化合物的用途,特别是制备药物组合物以允许或提高有需要的受试者的癌症治疗效率。 本发明的化合物与至少一种化学治疗药物的组合确实可以有利地用于治疗癌症,用于预防癌症转移和/或预防受试者的癌症复发。 本发明还公开了用于预防或治疗受试者的癌症,癌症转移和/或癌症复发的方法,以及适用于制备根据本发明的组合物和/或用于实施本文描述的方法的试剂盒。